Staffing and Research Support Payments. CFFT will make the payments to Vertex specified below during 2004 and 2005 in support of the Research Program under this Agreement. [***] [***] [***] [***] [***] [***] Vertex will dedicate a minimum average [***] during its term, [***] Unless otherwise agreed in writing by CFFT, from and after the earlier of the date upon which Vertex notifies CFFT of its selection of a Primary and an Alternate Program, Vertex will devote [***] to the Alternate Program, and will apply [***]. Subject to the foregoing requirements, the research support specified above can be allocated as Vertex may determine in good faith between in-house and outside resources, between the Primary Program and the Alternative Program, and between and among individual budget line items.
Staffing and Research Support Payments. NOVARTIS has made or will make the payments specified below to VERTEX during each Research Year in support of the Research Program under this Research Agreement. CONFIDENTIAL TREATMENT REQUESTED The required payments are based upon the following assumptions: (a) the average number of FTE's which VERTEX will have employed in the Research Program during a Research Year will be approximately equal to the FTE Level listed in the third column below; and (b) the annual rate per FTE is approximately [***]. If the average FTE level for any Research Year is less than the level specified below for that year (the difference being referred to in this section as an "FTE Shortfall"), then the amount of funding specified below for that Research Year shall be reduced by an amount (the "FTE Shortfall Amount") which bears the same relation to the total funding specified below for that Research Year as the FTE Shortfall bears to the projected FTE Level for that Year. The FTE Shortfall Amount shall be carried over from year to year and applied to compensate VERTEX for FTE Levels in subsequent Research Years which exceed the level for those Years as specified below. In any such subsequent Research Year, VERTEX shall be entitled to receive out of any remaining FTE Shortfall Amount a payment equal to the value (computed with reference to the inflation-adjusted FTE rate specified above) of any FTE's actually employed during that Research Year in excess of the FTE Level specified for that year ("Excess FTE's"). Notwithstanding the foregoing, the FTE Shortfall Amount will not be applied to compensate VERTEX on account of more than 20 Excess FTE's in any one Research Year. Research Year 1 will be deemed to have commenced on May 1, 2000. Payments due for each Research Year shall be made quarterly in advance on or before May 1, August 1, November 1 and February 1 of each Research Year except that the quarterly payment due May 1, 2000 was made within thirty business days after the Effective Date of this Research Agreement. All payments shall be made without deduction for withholding or other similar taxes, in United States dollars to the credit of such bank account as may be designated by VERTEX in writing to NOVARTIS. Any payments which fall due on a date which is a legal holiday in the Commonwealth of Massachusetts may be made on the next following day which is not a legal holiday in the Commonwealth.
Staffing and Research Support Payments. NIBRI will pay to Myogen: (a) [/\#/\]. The JSC shall determine the exact number of FTEs to be funded by NIBRI in any particular Research Year and the manner in which such FTEs shall be allocated under the Research Program. Between [/\#/\] FTEs shall be funded by NIBRI in any Research Year in connection with the Research Program. Any FTEs greater than [/\#/\]CONFIDENTIAL TREATMENT REQUESTED [/\#/\] require NIBRI's prior approval. The annual rate per FTE shall be [/\#/\]. The FTEs shall be funded in support of the Research Program under this Agreement. Payments due for each Research Year shall be made by NIBRI to Myogen [/\#/\]. All payments shall be made without deduction for withholding or other similar taxes, in United States dollars to the credit of such bank account as may be designated by Myogen in writing to NIBRI. Any payments which fall due on a date which is a legal holiday in the Commonwealth of Massachusetts may be made on the next following day which is not a legal holiday in the Commonwealth. In the event that NIBRI terminates its participation in the Research Program pursuant to Section 9.4, it shall nevertheless continue during the Wind-Down Period to fund: [/\#/\]
Staffing and Research Support Payments. CFFT will make the payments to Vertex specified below during 2004 and 2005 in support of the Research Program under this Agreement. Vertex will dedicate a minimum average [***] during its term, [***] Unless otherwise agreed in writing by CFFT, from and after the earlier of the date upon which Vertex notifies CFFT of its selection of a Primary and an Alternate Program, Vertex will devote [***] to the Alternate Program, and will apply [***]. Subject to the foregoing requirements, the research support specified above can be allocated as Vertex may determine in good faith between in-house and outside resources, between the Primary Program and the Alternative Program, and between and among individual budget line items.
Staffing and Research Support Payments. CFFT will make the payments to Predix specified below during the Term in support of the Research Programs under this Agreement.
3.1.1. RESEARCH PROGRAM I Item in Estimated FTE Out-sourced Total Exhibit 2.4 Time Research activities Budgeted (Months)* Funding (# Amount FTEs charged at $[******* **********]
a) [******************]: to be paid on the date of execution $2,000,000
b) Base Research Funding: Modeling the [**] and [**] or less $[*****](6) $[*****]; $[********] 3D structure [**] $[*****] of [*********** ********* *******] and ********** [******* *********] Structure [**] and [**] or less $[*****](6) $[***** $[********] based [**] *****] analysis and experimental validation of [********* ******] and [******** ********] Modeling 3D [**] [**] or less $[*****](6) $[******** $[*********] structure of ********* the [******** ********] ********* **********] Structure [**] [**] or less $*****](6) $[******** $[********] based ********] analysis and Experimental validation of [**********] PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO THE COMPANY'S APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE EXCHANGE ACT; [*] DENOTES OMISSIONS. EXECUTION COPY
Staffing and Research Support Payments. NIBRI will pay to Myogen: (a) [..**..]; and (b) [..**..
Staffing and Research Support Payments. CFFT will make the payments to Vertex specified below during 2004 and 2005 in support of the Research Program under this Agreement. Vertex will dedicate a minimum average [***] during its term, [***]. Unless otherwise agreed in writing by CFFT, from and after the earlier of the date upon which Vertex notifies CFFT of its selection of a Primary and an Alternate Program, Vertex will devote [***] to the Alternate Program, and will apply [***]. Subject to the foregoing requirements, the research support specified above can be allocated as Vertex may determine in good faith between * Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. in-house and outside resources, between the Primary Program and the Alternative Program, and between and among individual budget line items.
Staffing and Research Support Payments. CFFT will make the payments to Predix specified below during the Term in support of the Research Programs under this Agreement.
Staffing and Research Support Payments. (a) CFFT will make payments to CombinatoRx in support of the Budget. The initial Budget shall cover estimated costs for the Research Program during each annual period encompassed by the Research Program prior to the Go Decision. If a Go Decision is made, CFFT will pay seventy-five percent (75%) and CombinatoRx will pay twenty-five percent (25%) (the “CombinatoRx Share”) of the Phase I and Phase IIa costs of the first Drug Product Candidate and the Budget shall be modified as part of the Go Decision process to project such costs. The Parties will negotiate in good faith with respect to any level of financial support CFFT will provide for any subsequent Drug Product Candidate. Any material revisions to the Budget which would result in an increase in total funding for the Research Program by CFFT will require the prior approval of CFFT.
(b) In addition to the foregoing, all licensing costs required to obtain a license necessary for the performance of the Research Program will be borne by CFFT after CFFT’s prior review and approval. Any royalties required by such license shall be subject to Section 5.9.
(c) Payments due under the Budget on account of internal FTEs shall be made by CFFT quarterly in advance, except the payment for the quarter following the Research Initiation Date shall be made pursuant to this subparagraph following receipt of an invoice submitted to CFFT by CombinatoRx after the Research Initiation Date. FTE’s shall be identified on invoices or in the budget by the individual constituting the FTEs. During the quarter following its invoicing, internal FTE shall be trued up to actual with appropriate adjustment to such quarter’s payment. Internal FTE costs will be calculated at an annual rate of $[*] per FTE. Payments due under the Budget on account of external costs shall be made by CFFT quarterly in arrears. Payment pursuant to this Section 4.1 shall be made within thirty (30) days following receipt of an invoice from CombinatoRx for such costs accompanied by reasonable documentation of such costs and, during Phase I and IIa of clinical development, reasonable evidence that CombinatoRx has paid the CombinatoRx Share. All payments shall be made without deduction for withholding or other similar taxes, in United States dollars to the credit of such bank account as may be designated by CombinatoRx in writing to CFFT. Any payments which are due on a date which is a legal holiday in the Commonwealth of Massachusetts may be made on the next followi...
Staffing and Research Support Payments
